Text and Data Mining valid from 2014-12-22
Received: 4 November 2013
Accepted: 8 October 2014
First Online: 22 December 2014
: This work was funded, in part, by Baxter Healthcare. Northwestern University holds the rights to two US and several international patents concerning antibodies that target Aβ oligomer assemblies. Acumen Pharmaceuticals holds the licensing rights to develop anti-Aβ oligomer antibodies for therapeutic use.